Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Quanta Services Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Quanta Services Inc trades at $679 (market cap $100.82B). The key difference: Quanta Services Inc is far larger — about 3.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Quanta Services Inc pays a 0.07% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PWR | |
|---|---|---|
Market Cap | $29.60B | $100.82B |
Sector | Health | Industrials |
52-Week High | $491.22 | $785.24 |
52-Week Low | $205.48 | $372.50 |
Enterprise Value | $27.56B | $106.91B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
PWR trades at $677.91, up 2.58% today, with strong technical momentum above key support at $664. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.24 beating expectations by 28%, revenue growth accelerating to $28.48B in 2025, and a record backlog supporting raised 2026 guidance. Analyst sentiment remains overwhelmingly positive with 72% buy ratings and a $809.75 consensus target.
PWR offers compelling growth exposure to infrastructure demand, particularly in power and data centers, but faces valuation concerns with a P/E of 76.7x. Near-term risks include execution on large projects and macroeconomic sensitivity, while institutional accumulation and strong cash flow generation support the bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
